Brief: Evelo Biosciences Presents Late-Breaking Oral Abstract On Data From Phase 2 Trial Of EDP1815 In Psoriasis
26/03/2022 17:27
March 26 (Reuters) - Evelo Biosciences Inc EVLO.O :
* EVELO BIOSCIENCES PRESENTS LATE-BREAKING ORAL ABSTRACT ON
DATA
FROM PHASE 2 TRIAL OF EDP1815 IN PSORIASIS
Source text for Eikon: ID:nGNX4ggK4R
Further company coverage: EVLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evelo Biosciences
See all newsU.S. RESEARCH ROUNDUP- Evelo Biosciences, Nkarta, O'Reilly Automotive
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Evelo Bio slumps after skin disease drug fails in mid-stage study
U.S. STOCKS ON THE MOVE-Nvidia, Westlake, North American steel companies
U.S. STOCKS ON THE MOVE-TMC, PayPal, TOMI